Imagine trying to find a tiny needle in a haystack before it even becomes a problem. This work creates smarter, cheaper tests and digital tools to spot ovarian cancer risks and early signs much faster than current methods. It's like upgrading a basic smoke alarm to a smart system that predicts a fire before it starts.
Ovarian cancer is often detected too late to be treated effectively. Current risk assessment and early detection methods are either too expensive, inaccurate, or not integrated into routine care.
A suite of affordable liquid biopsy technologies and AI-powered digital assets for risk assessment and early detection.
If you are a kit manufacturer dealing with low accuracy in early cancer detection — this project developed validated liquid biopsy technologies that provide highly accurate and affordable screening.
If you are a software provider dealing with inefficient patient risk stratification — this project developed intelligent digital assets that support clinical risk assessment across 4 EU Member States.
If you are a clinic network dealing with high costs of hereditary cancer management — this project developed a set of easy-to-use technologies to upscale routine healthcare screening in 5 countries.
Based on available project data, specific pricing is not mentioned, but the project explicitly aims to create 'affordable technologies'.
Yes, the project focuses on upscaling and validating technologies in 5 countries, including the UK, Lithuania, Portugal, Czech Republic, and Greece.
Based on available project data, specific licensing terms are not provided, though the project involves 8 industry partners and 7 SMEs.
The project runs from 2025-09-01 to 2029-08-31.
The project focuses on rolling out proven solutions into routine ovarian cancer risk assessment and early detection programmes.
The project features a strong commercial orientation with 8 industry partners and 7 SMEs, representing a 29% industry ratio. The broad geographic footprint across 12 countries, including Canada and the UK, suggests a high capacity for international market entry and cross-border validation of the medical tools.
Contact EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTON in Greece
Contact us to connect with the DISARM consortium for licensing opportunities.
